Author Correction: Diagnosis and management of Silver–Russell syndrome: second international consensus statement - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Updated Consensus on the Diagnosis and Treatment of Silver–Russell Syndrome from the Second International Meeting

  • By

  • Emma Wakeling

  • Justin H. Davies

  • Eloïse Giabicani

  • Susan M. O’Connell

  • Madeleine D. Harbison

  • Amélie Perriere

  • Jennifer B. Salem

  • Matthias Begemann

  • Gerhard Binder

  • Frédéric Brioude

  • Dayna Morris-Carney

  • Jovanna Dahlgren

  • Bea Dickinson

  • Bruno Donadille

  • Beatrice Dubern

  • Katja Eggermann

  • Gabriella Gazdagh

  • Karen Grønskov

  • Anita C. Hokken Koelega

  • Youn Hee Jee

  • Alicia Jurians

  • Masayo Kagami

  • Satomi Koyama

  • Emilie Kulak

  • Asmahane Ladjouze

  • Paola Lombardi

  • Mohamad Maghnie

  • Louise McClelland

  • Veronica Mericq

  • Giuseppa Patti

  • Klaudia Raabe

  • Andrea Riccio

  • Silvia Russo

  • Helen L. Storr

  • I. Karen Temple

  • Zeynep Tümer

  • Thomas Eggermann

  • Deborah J. G. Mackay

  • Irene Netchine

  • September 30, 2026

Share

Clinical Report: Correction Notice on Silver–Russell Syndrome Consensus

Background

Silver–Russell Syndrome is a growth disorder characterized by prenatal and postnatal growth failure, among other features. Accurate diagnosis is crucial for effective management. The updated consensus aims to refine diagnostic criteria and treatment approaches for SRS.

Data Highlights

No numerical or trial data is presented in this correction notice.

Key Findings

  • The name of author Giuseppa Patti was corrected from Guiseppa.
  • The consensus emphasizes molecular diagnostic criteria, including maternal uniparental disomy of chromosome 7.
  • Loss of methylation at 11p15 H19/IGF2:IG-DMR is highlighted as a key diagnostic marker.
  • Multidisciplinary management is recommended to address various clinical issues associated with SRS.
  • Approximately 40% of clinically suspected SRS cases do not achieve a molecular diagnosis.

Clinical Implications

Healthcare professionals should ensure accurate author attribution in published works. The updated consensus provides essential guidelines for the diagnosis and management of SRS.

Conclusion

The correction notice serves to clarify author details in the context of important updates on SRS management and diagnosis.

Related Resources & Content

  1. Vimercati A et al., Nature Reviews Endocrinology, 2026 -- Correction Notice: Updated Consensus on the Diagnosis and Treatment of Silver–Russell Syndrome
  2. The Journal of Clinical Endocrinology & Metabolism — Silver-Russell Syndrome in 2025: Is It Still a Distinct Diagnostic Entity?
  3. The Journal of Clinical Endocrinology & Metabolism — Erratum: “Differentiating Genetic Modifications from (Epi)Mutations in Silver–Russell Syndrome with Emphasis on the IGF1R Gene”
  4. The Journal of Clinical Endocrinology & Metabolism — Differentiating Between Genetic Variants and (Epi)Mutations in Silver–Russell Syndrome with Emphasis on the IGF1R Gene
  5. Journal of Neuro-Oncology — Amendment to: Pediatric Central Nervous System Tumors in Patients Aged Under 5: Insights on Treatment Challenges, Survival Rates, and Long-Term Outcomes
  6. Diagnosis and management of Silver–Russell syndrome: second international consensus statement | Nature Reviews Endocrinology
  7. https://www.eshg.org/fileadmin/user_upload/Guideline_Growth_genetics_Oct_01_2025.pdf
  8. oup.silverchair-cdn.com
  9. Does earlier initiation of growth hormone therapy improve outcomes in children with Silver-Russell syndrome?
  10. Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial | European Journal of Endocrinology | Oxford Academic
  11. PEG10 loss of function causes Silver-Russell syndrome: a familial case with paternal deletion | Scientific Reports

Original Source(s)

Author Correction: Diagnosis and management of Silver–Russell syndrome: second international consensus statement

  • by Emma Wakeling, Justin H. Davies, Eloïse Giabicani, Susan M. O’Connell, Madeleine D. Harbison, Amélie Perriere, Jennifer B. Salem, Matthias Begemann, Gerhard Binder, Frédéric Brioude, Dayna Morris-Carney, Jovanna Dahlgren, Bea Dickinson, Bruno Donadille, Beatrice Dubern, Katja Eggermann, Gabriella Gazdagh, Karen Grønskov, Anita C. Hokken Koelega, Youn Hee Jee, Alicia Jurians, Masayo Kagami, Satomi Koyama, Emilie Kulak, Asmahane Ladjouze, Paola Lombardi, Mohamad Maghnie, Louise McClelland, Veronica Mericq, Giuseppa Patti, Klaudia Raabe, Andrea Riccio, Silvia Russo, Helen L. Storr, I. Karen Temple, Zeynep Tümer, Thomas Eggermann, Deborah J. G. Mackay, Irene Netchine

  • September 30, 2026

Related Content

Smoking Cessation Duration and Diabetic Microvascular Complications

Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity

Weight-loss and body-composition trajectories after bariatric surgery may follow different timelines